DexCom, Inc. (DXCM) — Analysis Summary
DexCom, Inc. (DXCM) has a market cap of $33.69B with year-over-year revenue growth of +15.6%. Net margin stands at 17.9%. The stock trades at a P/E ratio of 33.7.
Key Takeaways
- Revenue changed +15.6% year-over-year
- Net margin of 17.9%
- P/E ratio of 33.7
Compared to other companies in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector, DXCM posted revenue growth of +15.6% and trades at a P/E of 33.7.
DexCom, Inc. (DXCM)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsNo Major Flags
No major credit, margin, or trend red flags were triggered from the latest filings.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Employees
11,100
Headquarters
SAN DIEGO, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.